Kyla Beedy
Family · Amarillo, TXNPI 1083921100
Payments from drug & device makers
Across 498 payments — averaging $107.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$29K
- Sanofi$17K
- Inspire Medical Systems, Inc.$2K
- GSK$2K
- AstraZeneca$873
- AbbVie$755
- plus $3K from 28 others
What the payments were for
- Consulting fees$2,1814%
- Speaking & faculty fees$33,06262%
- Travel & lodging$8,79816%
- Food & beverage$9,33217%
- Education$3161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 80 | $28,601 |
| Sanofi | 64 | $17,091 |
| Inspire Medical Systems, Inc. | 20 | $1,910 |
| GSK | 111 | $1,604 |
| AstraZeneca | 36 | $873 |
| AbbVie | 42 | $755 |
| Harmony Biosciences LLC | 17 | $508 |
| Boehringer Ingelheim | 19 | $421 |
| Mylan Specialty L.p. | 26 | $410 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $272 |
| Genentech USA, Inc. | 17 | $257 |
| Medtronic | 1 | $156 |
| Sanofi-aventis U.S. LLC | 3 | $134 |
| Actelion Pharmaceuticals US, Inc. | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| EMD Serono, Inc. | 2 | $48 |
| United Therapeutics Corporation | 3 | $47 |
| Grifols USA, LLC | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Merck | 2 | $38 |
| Amgen(2 entities) | 2 | $36 |
| Baxter Healthcare | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Philips North America LLC | 2 | $31 |
| Vertex | 1 | $31 |
| Lilly USA, LLC | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 1 | $26 |
| Inogen, Inc. | 5 | $23 |
| Eisai Inc. | 1 | $22 |
| Vapotherm Inc | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Insmed, Inc. | 1 | $13 |
| SK Life Science, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,688 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $55,659 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $34,064 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $15,182 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $14,233 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $11,575 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,827 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $2,105 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,001 |
| Amitriptyline Hcl | 61 | $608 |
| Ropinirole Hcl | 50 | $560 |
| Trazodone Hcl | 86 | $445 |
| Modafinil | 15 | $298 |
| Eszopiclone | 14 | $195 |
| Bupropion Hcl SrBupropion Hcl | 13 | $182 |
| Gabapentin | 30 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,604 | $85,074147 claims |
| AstraZenecaBreztri Aerosphere | $873 | $34,06441 claims |
| Boehringer IngelheimStiolto Respimat | $421 | $11,57515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Amarillo
- Tiffany RandleAmarillo$50K
- Cory PickettAmarillo$34K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.